These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37405651)

  • 21. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions.
    Matta J; Baratin M; Chiche L; Forel JM; Cognet C; Thomas G; Farnarier C; Piperoglou C; Papazian L; Chaussabel D; Ugolini S; Vély F; Vivier E
    Blood; 2013 Jul; 122(3):394-404. PubMed ID: 23687088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
    Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
    J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.
    Brandt CS; Baratin M; Yi EC; Kennedy J; Gao Z; Fox B; Haldeman B; Ostrander CD; Kaifu T; Chabannon C; Moretta A; West R; Xu W; Vivier E; Levin SD
    J Exp Med; 2009 Jul; 206(7):1495-503. PubMed ID: 19528259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20.
    Charpak-Amikam Y; Kubsch T; Seidel E; Oiknine-Djian E; Cavaletto N; Yamin R; Schmiedel D; Wolf D; Gribaudo G; Messerle M; Cicin-Sain L; Mandelboim O
    Sci Rep; 2017 Aug; 7(1):8661. PubMed ID: 28819195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.
    Butler SE; Brog RA; Chang CH; Sentman CL; Huang YH; Ackerman ME
    Cancer Immunol Immunother; 2022 Jan; 71(1):165-176. PubMed ID: 34046711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
    Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
    MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
    Zhang T; Wu MR; Sentman CL
    J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies.
    Lee S; Kim JH; Jang IH; Jo S; Lee SY; Oh SC; Kim SM; Kong L; Ko J; Kim TD
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.
    Phillips M; Romeo F; Bitsaktsis C; Sabatino D
    Biopolymers; 2016 Sep; 106(5):658-72. PubMed ID: 27216712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling.
    Cao G; Cheng Y; Zheng X; Wei H; Tian Z; Sun R; Sun H
    Cancer Commun (Lond); 2021 Jan; 41(1):51-61. PubMed ID: 34236140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production.
    Salimi M; Xue L; Jolin H; Hardman C; Cousins DJ; McKenzie AN; Ogg GS
    J Immunol; 2016 Jan; 196(1):45-54. PubMed ID: 26582946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site.
    Joyce MG; Tran P; Zhuravleva MA; Jaw J; Colonna M; Sun PD
    Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6223-8. PubMed ID: 21444796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.
    Hua CK; Gacerez AT; Sentman CL; Ackerman ME
    Protein Eng Des Sel; 2017 Oct; 30(10):713-721. PubMed ID: 29040754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The B7 Family Member B7-H6: a New Bane of Tumor.
    Chen Y; Mo J; Jia X; He Y
    Pathol Oncol Res; 2018 Oct; 24(4):717-721. PubMed ID: 29086181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells.
    Binici J; Hartmann J; Herrmann J; Schreiber C; Beyer S; Güler G; Vogel V; Tumulka F; Abele R; Mäntele W; Koch J
    J Biol Chem; 2013 Nov; 288(48):34295-303. PubMed ID: 24133212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.
    Mantovani S; Oliviero B; Lombardi A; Varchetta S; Mele D; Sangiovanni A; Rossi G; Donadon M; Torzilli G; Soldani C; Porta C; Pedrazzoli P; Chiellino S; Santambrogio R; Opocher E; Maestri M; Bernuzzi S; Rossello A; Clément S; De Vito C; Rubbia-Brandt L; Negro F; Mondelli MU
    Hepatology; 2019 Mar; 69(3):1165-1179. PubMed ID: 30153337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential of B7-H6 as a therapeutic target in cancer immunotherapy.
    Mohammadi A; Najafi S; Amini M; Mansoori B; Baghbanzadeh A; Hoheisel JD; Baradaran B
    Life Sci; 2022 Sep; 304():120709. PubMed ID: 35697295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NKp30 - A prospective target for new cancer immunotherapy strategies.
    Pinheiro PF; Justino GC; Marques MM
    Br J Pharmacol; 2020 Oct; 177(20):4563-4580. PubMed ID: 32737988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.
    Textor S; Bossler F; Henrich KO; Gartlgruber M; Pollmann J; Fiegler N; Arnold A; Westermann F; Waldburger N; Breuhahn K; Golfier S; Witzens-Harig M; Cerwenka A
    Oncoimmunology; 2016 Jul; 5(7):e1116674. PubMed ID: 27622013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B7H6 is a functional ligand for NKp30 in rat and cattle and determines NKp30 reactivity toward human cancer cell lines.
    Bjørnsen EG; Thiruchelvam-Kyle L; Hoelsbrekken SE; Henden C; Saether PC; Boysen P; Daws MR; Dissen E
    Eur J Immunol; 2019 Jan; 49(1):54-65. PubMed ID: 30512185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.